top of page

Unlocking the Power of
Natural Killer Cell Therapeutics

Home: Welcome

Precision Gene Editing to Unlock the Power of iPSC-Derived NK Cells

“We are excited to collaborate with Cellectis, a gene-editing pioneer and leader in the de

Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 ASH Annual Meeting

December 9th, 2022

Cytovia Presents New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Bispecific Antibodies at 2022 SITC Annual Meeting

November 7th, 2022

See All News & Events

Cytovia Therapeutics To Present New Data on CD38 Flex-NK™ Bispecific Antibodies for Multiple Myeloma at ASH 2022 Annual Meeting

October 27th, 2022

What's New at Cytovia

bottom of page